Chemical and Functional Analysis of Hydroxyurea Oral Solutions

Matthew M. Heeney, Matthew Whorton, Thad A. Howard, Christina A. Johnson, Russell E. Ware

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The primary hypothesis of the upcoming NIH-sponsored phase III infant hydroxyurea (BABY HUG) trial is that hydroxyurea can prevent chronic organ damage in infants with sickle cell anemia. Since hydroxyurea is currently commercially available only in capsules, a liquid formulation of hydroxyurea is needed for young patients. Hydroxyurea oral solutions were prepared by dissolving the contents of the capsules in water (room temperature or mildly heated) with vigorous stirring, filtering excipients, and adding flavored syrup to a final concentration of 100 mg/mL. Chemical stability was determined by measuring the hydroxyurea concentration using a standardized analytical colorimetric analysis, while functional stability was determined by measuring the inhibition of phytohemagglutinin-induced T lymphocyte proliferation. Hydroxyurea oral solutions prepared using room-temperature water had statistically equivalent spectrophotometric concentration and inhibition of T-lymphocyte proliferation for 3 to 6 months. Mild heating of the water to facilitate dissolution of the hydroxyurea capsule contents resulted in a reduced concentration and inhibitory activity of the preparations. Hydroxyurea oral solutions (100 mg/mL) prepared and maintained at room temperature have chemical and functional stability for several months. Hydroxyurea oral solutions prepared and dispensed monthly are suitable for use in the upcoming infant BABY HUG trial.

Original languageEnglish (US)
Pages (from-to)179-184
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume26
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Hydroxyurea
Capsules
Temperature
Water
T-Lymphocytes
Excipients
Sickle Cell Anemia
Phytohemagglutinins
Heating

Keywords

  • Children
  • Hydroxyurea
  • Oral solutions
  • Sickle cell anemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Chemical and Functional Analysis of Hydroxyurea Oral Solutions. / Heeney, Matthew M.; Whorton, Matthew; Howard, Thad A.; Johnson, Christina A.; Ware, Russell E.

In: Journal of Pediatric Hematology/Oncology, Vol. 26, No. 3, 03.2004, p. 179-184.

Research output: Contribution to journalArticle

Heeney, Matthew M. ; Whorton, Matthew ; Howard, Thad A. ; Johnson, Christina A. ; Ware, Russell E. / Chemical and Functional Analysis of Hydroxyurea Oral Solutions. In: Journal of Pediatric Hematology/Oncology. 2004 ; Vol. 26, No. 3. pp. 179-184.
@article{a2e434e4b6b048bdac3601655da97169,
title = "Chemical and Functional Analysis of Hydroxyurea Oral Solutions",
abstract = "The primary hypothesis of the upcoming NIH-sponsored phase III infant hydroxyurea (BABY HUG) trial is that hydroxyurea can prevent chronic organ damage in infants with sickle cell anemia. Since hydroxyurea is currently commercially available only in capsules, a liquid formulation of hydroxyurea is needed for young patients. Hydroxyurea oral solutions were prepared by dissolving the contents of the capsules in water (room temperature or mildly heated) with vigorous stirring, filtering excipients, and adding flavored syrup to a final concentration of 100 mg/mL. Chemical stability was determined by measuring the hydroxyurea concentration using a standardized analytical colorimetric analysis, while functional stability was determined by measuring the inhibition of phytohemagglutinin-induced T lymphocyte proliferation. Hydroxyurea oral solutions prepared using room-temperature water had statistically equivalent spectrophotometric concentration and inhibition of T-lymphocyte proliferation for 3 to 6 months. Mild heating of the water to facilitate dissolution of the hydroxyurea capsule contents resulted in a reduced concentration and inhibitory activity of the preparations. Hydroxyurea oral solutions (100 mg/mL) prepared and maintained at room temperature have chemical and functional stability for several months. Hydroxyurea oral solutions prepared and dispensed monthly are suitable for use in the upcoming infant BABY HUG trial.",
keywords = "Children, Hydroxyurea, Oral solutions, Sickle cell anemia",
author = "Heeney, {Matthew M.} and Matthew Whorton and Howard, {Thad A.} and Johnson, {Christina A.} and Ware, {Russell E.}",
year = "2004",
month = "3",
doi = "10.1097/00043426-200403000-00007",
language = "English (US)",
volume = "26",
pages = "179--184",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chemical and Functional Analysis of Hydroxyurea Oral Solutions

AU - Heeney, Matthew M.

AU - Whorton, Matthew

AU - Howard, Thad A.

AU - Johnson, Christina A.

AU - Ware, Russell E.

PY - 2004/3

Y1 - 2004/3

N2 - The primary hypothesis of the upcoming NIH-sponsored phase III infant hydroxyurea (BABY HUG) trial is that hydroxyurea can prevent chronic organ damage in infants with sickle cell anemia. Since hydroxyurea is currently commercially available only in capsules, a liquid formulation of hydroxyurea is needed for young patients. Hydroxyurea oral solutions were prepared by dissolving the contents of the capsules in water (room temperature or mildly heated) with vigorous stirring, filtering excipients, and adding flavored syrup to a final concentration of 100 mg/mL. Chemical stability was determined by measuring the hydroxyurea concentration using a standardized analytical colorimetric analysis, while functional stability was determined by measuring the inhibition of phytohemagglutinin-induced T lymphocyte proliferation. Hydroxyurea oral solutions prepared using room-temperature water had statistically equivalent spectrophotometric concentration and inhibition of T-lymphocyte proliferation for 3 to 6 months. Mild heating of the water to facilitate dissolution of the hydroxyurea capsule contents resulted in a reduced concentration and inhibitory activity of the preparations. Hydroxyurea oral solutions (100 mg/mL) prepared and maintained at room temperature have chemical and functional stability for several months. Hydroxyurea oral solutions prepared and dispensed monthly are suitable for use in the upcoming infant BABY HUG trial.

AB - The primary hypothesis of the upcoming NIH-sponsored phase III infant hydroxyurea (BABY HUG) trial is that hydroxyurea can prevent chronic organ damage in infants with sickle cell anemia. Since hydroxyurea is currently commercially available only in capsules, a liquid formulation of hydroxyurea is needed for young patients. Hydroxyurea oral solutions were prepared by dissolving the contents of the capsules in water (room temperature or mildly heated) with vigorous stirring, filtering excipients, and adding flavored syrup to a final concentration of 100 mg/mL. Chemical stability was determined by measuring the hydroxyurea concentration using a standardized analytical colorimetric analysis, while functional stability was determined by measuring the inhibition of phytohemagglutinin-induced T lymphocyte proliferation. Hydroxyurea oral solutions prepared using room-temperature water had statistically equivalent spectrophotometric concentration and inhibition of T-lymphocyte proliferation for 3 to 6 months. Mild heating of the water to facilitate dissolution of the hydroxyurea capsule contents resulted in a reduced concentration and inhibitory activity of the preparations. Hydroxyurea oral solutions (100 mg/mL) prepared and maintained at room temperature have chemical and functional stability for several months. Hydroxyurea oral solutions prepared and dispensed monthly are suitable for use in the upcoming infant BABY HUG trial.

KW - Children

KW - Hydroxyurea

KW - Oral solutions

KW - Sickle cell anemia

UR - http://www.scopus.com/inward/record.url?scp=1542376824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542376824&partnerID=8YFLogxK

U2 - 10.1097/00043426-200403000-00007

DO - 10.1097/00043426-200403000-00007

M3 - Article

C2 - 15125610

AN - SCOPUS:1542376824

VL - 26

SP - 179

EP - 184

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -